TrialSignal transduction and targeted therapy2026

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.

Yue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.